208 related articles for article (PubMed ID: 21248155)
1. Evaluation of the immunogenicity and biological activity of the Citrobacter freundii Vi-CRM197 conjugate as a vaccine for Salmonella enterica serovar Typhi.
Rondini S; Micoli F; Lanzilao L; Hale C; Saul AJ; Martin LB
Clin Vaccine Immunol; 2011 Mar; 18(3):460-8. PubMed ID: 21248155
[TBL] [Abstract][Full Text] [Related]
2. Vi-CRM 197 as a new conjugate vaccine against Salmonella Typhi.
Micoli F; Rondini S; Pisoni I; Proietti D; Berti F; Costantino P; Rappuoli R; Szu S; Saul A; Martin LB
Vaccine; 2011 Jan; 29(4):712-20. PubMed ID: 21115057
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of two WHO First International Standards for Vi polysaccharide from Citrobacter freundii and Salmonella enterica subspecies enterica serovar Typhi.
Gao F; Swann C; Rigsby P; Rijpkema S; Lockyer K; Logan A; Bolgiano B;
Biologicals; 2019 Jan; 57():34-45. PubMed ID: 30502020
[TBL] [Abstract][Full Text] [Related]
4. First characterization of immunogenic conjugates of Vi negative Salmonella Typhi O-specific polysaccharides with rEPA protein for vaccine development.
Salman M; St Michael F; Ali A; Jabbar A; Cairns C; Hayes AC; Rahman M; Iqbal M; Haque A; Cox AD
J Immunol Methods; 2017 Nov; 450():27-33. PubMed ID: 28735760
[TBL] [Abstract][Full Text] [Related]
5. Physical and chemical characterization and immunologic properties of Salmonella enterica serovar typhi capsular polysaccharide-diphtheria toxoid conjugates.
Cui C; Carbis R; An SJ; Jang H; Czerkinsky C; Szu SC; Clemens JD
Clin Vaccine Immunol; 2010 Jan; 17(1):73-9. PubMed ID: 19889941
[TBL] [Abstract][Full Text] [Related]
6. Vi Capsular Polysaccharide Produced by Recombinant
Xiong K; Zhu C; Chen Z; Zheng C; Tan Y; Rao X; Cong Y
Front Cell Infect Microbiol; 2017; 7():135. PubMed ID: 28484685
[TBL] [Abstract][Full Text] [Related]
7. Production of a conjugate vaccine for Salmonella enterica serovar Typhi from Citrobacter Vi.
Micoli F; Rondini S; Pisoni I; Giannelli C; Di Cioccio V; Costantino P; Saul A; Martin LB
Vaccine; 2012 Jan; 30(5):853-61. PubMed ID: 22172503
[TBL] [Abstract][Full Text] [Related]
8. Characterization of Citrobacter sp. line 328 as a source of Vi for a Vi-CRM(197) glycoconjugate vaccine against Salmonella Typhi.
Rondini S; Micoli F; Lanzilao L; Pisoni I; Di Cioccio V; Saul AJ; Martin LB
J Infect Dev Ctries; 2012 Nov; 6(11):763-73. PubMed ID: 23277501
[TBL] [Abstract][Full Text] [Related]
9. Determination of free polysaccharide in Vi glycoconjugate vaccine against typhoid fever.
Giannelli C; Cappelletti E; Di Benedetto R; Pippi F; Arcuri M; Di Cioccio V; Martin LB; Saul A; Micoli F
J Pharm Biomed Anal; 2017 May; 139():143-147. PubMed ID: 28282600
[TBL] [Abstract][Full Text] [Related]
10. Development of a synthetic Vi polysaccharide vaccine for typhoid fever.
Ni Y; Springer MJ; Guo J; Finger-Baker I; Wilson JP; Cobb RR; Turner D; Tizard I
Vaccine; 2017 Dec; 35(51):7121-7126. PubMed ID: 29150208
[TBL] [Abstract][Full Text] [Related]
11. Immunization with the conjugate vaccine Vi-CRM₁₉₇ against Salmonella typhi induces Vi-specific mucosal and systemic immune responses in mice.
Fiorino F; Ciabattini A; Rondini S; Pozzi G; Martin LB; Medaglini D
Vaccine; 2012 Sep; 30(43):6111-4. PubMed ID: 22705173
[TBL] [Abstract][Full Text] [Related]
12. The influence of conjugation variables on the design and immunogenicity of a glycoconjugate vaccine against Salmonella Typhi.
Arcuri M; Di Benedetto R; Cunningham AF; Saul A; MacLennan CA; Micoli F
PLoS One; 2017; 12(12):e0189100. PubMed ID: 29287062
[TBL] [Abstract][Full Text] [Related]
13. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children.
Lin FY; Ho VA; Khiem HB; Trach DD; Bay PV; Thanh TC; Kossaczka Z; Bryla DA; Shiloach J; Robbins JB; Schneerson R; Szu SC
N Engl J Med; 2001 Apr; 344(17):1263-9. PubMed ID: 11320385
[TBL] [Abstract][Full Text] [Related]
14. In vitro characterization and preclinical immunogenicity of Typhax, a typhoid fever protein capsular matrix vaccine candidate.
Griffin TJ; Thanawastien A; Cartee RT; Mekalanos JJ; Killeen KP
Hum Vaccin Immunother; 2019; 15(6):1310-1316. PubMed ID: 31021700
[TBL] [Abstract][Full Text] [Related]
15. Physico-chemical properties of Salmonella typhi Vi polysaccharide-diphtheria toxoid conjugate vaccines affect immunogenicity.
An SJ; Yoon YK; Kothari S; Kothari N; Kim JA; Lee E; Kim DR; Park TH; Smith GW; Carbis R
Vaccine; 2011 Oct; 29(44):7618-23. PubMed ID: 21843575
[TBL] [Abstract][Full Text] [Related]
16. Development of Vi conjugate - a new generation of typhoid vaccine.
Szu SC
Expert Rev Vaccines; 2013 Nov; 12(11):1273-86. PubMed ID: 24156285
[TBL] [Abstract][Full Text] [Related]
17. Re-examination of immune response and estimation of anti-Vi IgG protective threshold against typhoid fever-based on the efficacy trial of Vi conjugate in young children.
Szu SC; Klugman KP; Hunt S
Vaccine; 2014 Apr; 32(20):2359-63. PubMed ID: 24630869
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: results from two randomised, observer-blind, age de-escalation, phase 2 trials.
Bhutta ZA; Capeding MR; Bavdekar A; Marchetti E; Ariff S; Soofi SB; Anemona A; Habib MA; Alberto E; Juvekar S; Khan RM; Marhaba R; Ali N; Malubay N; Kawade A; Saul A; Martin LB; Podda A
Lancet Infect Dis; 2014 Feb; 14(2):119-29. PubMed ID: 24290843
[TBL] [Abstract][Full Text] [Related]
19. Engineering, conjugation, and immunogenicity assessment of Escherichia coli O121 O antigen for its potential use as a typhoid vaccine component.
Wetter M; Kowarik M; Steffen M; Carranza P; Corradin G; Wacker M
Glycoconj J; 2013 Jul; 30(5):511-22. PubMed ID: 23053636
[TBL] [Abstract][Full Text] [Related]
20. A bivalent conjugate vaccine containing PspA families 1 and 2 has the potential to protect against a wide range of Streptococcus pneumoniae strains and Salmonella Typhi.
Kothari N; Kothari S; Choi YJ; Dey A; Briles DE; Rhee DK; Carbis R
Vaccine; 2015 Feb; 33(6):783-8. PubMed ID: 25545593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
